New combo before lung surgery shows promise but trial cut short

NCT ID NCT03237377

Terminated Disease control Sponsor: Sidney Kimmel Comprehensive Cancer Center at Johns Hopkins Source: ClinicalTrials.gov ↗

First seen Jun 25, 2026 · Last updated Jun 27, 2026 · Updated 1 time

Summary

This pilot study tested giving immunotherapy drugs (durvalumab with or without tremelimumab) along with radiation before surgery for stage III non-small cell lung cancer. Only 9 people took part, and the trial was stopped early. The goal was to see if this combination was safe and feasible without delaying surgery.

What this could mean

Our plain-language read of the trial. This is informational only — not medical advice or a prediction.

Active substance: Durvalumab (immunotherapy) and tremelimumab (immunotherapy) plus thoracic radiation
What this could lead to: If successful, this approach could improve outcomes for patients with stage III lung cancer by shrinking tumors before surgery and potentially reducing recurrence.
What could go wrong: This was a very small, early pilot study (only 9 participants) that was terminated early, so results are limited. Combining immunotherapy with radiation also carries risks of serious side effects.

This is an AI summary of the original study and may miss details. Read our disclaimer.

Get updates

Get notified about this study

Sign up to get updates when this study changes or when new studies for NON-SMALL CELL LUNG CANCER are added.

Our safety recommendation!

By submitting, you agree to our Terms of use

Conditions

The condition(s) this trial relates to.

non-small cell lung carcinoma

As listed by the trial registrant

The condition terms exactly as the trial's registrant entered them.

NON-SMALL CELL LUNG CANCER

Contacts and locations

Locations

Johns Hopkins Bayview Medical Center

Baltimore, Maryland, 21224, United States
Princess Margaret Cancer Centre

Toronto, Ontario, Canada

More trials for these conditions

Other studies related to the condition(s) this trial covers.